Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Riociguat - Bayer

Drug Profile

Riociguat - Bayer

Alternative Names: Adempas; BAY-32521; BAY-63-2521

Latest Information Update: 09 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class 2 ring heterocyclic compounds; Antifibrotics; Carbamates; Diamines; Fluorobenzenes; Pyrazoles; Pyridines; Pyrimidines; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Pulmonary hypertension; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase II Cystic fibrosis; Raynaud's disease; Systemic scleroderma

Most Recent Events

  • 08 Sep 2020 Efficacy and safety data from the phase III PATENT-1 trial in Pulmonary arterial hypertension release by Bayer
  • 03 Jun 2020 Efficacy and adverse event data from the phase II RISE-SSc trial in Systemic scleroderma presented at the 21st Annual Congress of the European League Against Rheumatism (EULAR-2020)
  • 08 Nov 2019 Efficacy and adverse events data from the phase II RESCUE trial in Systemic scleroderma presented at the 83rd American College of Rheumatology and the 54th Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top